[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100511874":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":23,"locations":29,"responsibleParty":47,"collaborators":49,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":18,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":18,"enrollmentInfo":64,"targetDuration":18,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":73,"overallStatus":31,"whyStopped":18,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"University of Michigan Rogel Cancer Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Cardio-oncology program","EXPERIMENTAL","The cardio-oncology program consists of a multimodal approach, which includes individualized exercise prescription following a detailed CV assessment and medical management of CV risk factors occurring over 8 weeks.",[13],"Other: Cardio-oncology program",[15],{"type":6,"name":9,"description":16,"armGroupLabels":17,"otherNames":18},"Consented patients will undergo an initial CV evaluation as part of standard of care then participate in an 8-week at-home, personalized exercise intervention followed by an additional CV assessment prior to HSCT (after 8-weeks)",[9],null,[20],{"name":21,"affiliation":5,"role":22},"Salim Hayek","PRINCIPAL_INVESTIGATOR",[24],{"name":25,"role":26,"phone":27,"phoneExt":18,"email":28},"Cancer AnswerLine","CONTACT","1-800-865-1125","CancerAnswerLine@med.umich.edu",[30],{"facility":5,"status":31,"city":32,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"RECRUITING","Ann Arbor","Michigan","48109","United States","US",{"type":38,"coordinates":39},"Point",[40,41],-83.74088,42.27756,{"lat":41,"lon":40},[44,46],{"name":25,"role":26,"phone":45,"phoneExt":18,"email":28},"800-865-1125",{"name":21,"role":22,"phone":18,"phoneExt":18,"email":18},{"type":48,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR",[50,53],{"name":51,"class":52},"National Institutes of Health (NIH)","NIH",{"name":54,"class":52},"National Heart, Lung, and Blood Institute (NHLBI)","100511874","prehabilitation-program-to-improve-cardiac-reserve-in-high-risk-patients-undergoing-hematopoietic-stem-cell-transplantation-100511874",false,"NCT05945121","Prehabilitation Program to Improve Cardiac Reserve in High-Risk Patients Undergoing Hematopoietic Stem Cell Transplantation","Cardio-Oncology Prehabilitation Program to Improve Cardiac Reserve in High-Risk Patients Undergoing Hematopoietic Stem Cell Transplantation","Inclusion Criteria:\n\n* Adult 18 years or older\n* Referred for HSCT evaluation\n* Presence of least one CV risk factor at enrollment (hypertension, hyperlipidemia, atrial fibrillation, obesity, heart failure, history of coronary artery disease, diabetes)\n* Able to ambulate unassisted\n* Ability to understand and the willingness to sign a written informed consent\n* Ability to use Polar Flow heart rate application\n\nExclusion Criteria:\n\n* Severe anemia (hemoglobin \\\u003C7 gm\u002Fdl)\n* Untreated high-risk coronary artery disease (left main, triple vessel disease)\n* Severe aortic stenosis\n* Recent fracture as assessed via self-report\n* Gross balance deficits\n* Severe pain with basic movement\n* Unable to ambulate unassisted or exercise\n* NYHA class IV heart failure\n* Adults unable to give consent, pregnant women, and prisoners are excluded from this study.","ALL","18 Years",{"count":65,"type":66},10,"ESTIMATED","INTERVENTIONAL",[69],"NA","To assess the feasibility and preliminary effectiveness of a Cardio-Oncology Prehabilitation program in patients at high-risk of developing Cardiovascular (CV) events in improving Cardiorespiratory fitness (CRF) and reducing acute CV complications in Hematopoietic stem cell transplant (HSCT) recipients.",[72],"Hematopoietic Stem Cell Transplant",[74],"Cardiovascular disease","2026-05-01",{"date":77,"type":78},"2026-05-04","ACTUAL",{"date":80,"type":78},"2023-08-25",{"date":82,"type":66},"2027-08",{"name":5,"class":6},1]